Condition
FL
Total Trials
3
Recruiting
0
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
P 1 (2)
P 2 (1)
Trial Status
Not Yet Recruiting2
Active Not Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT03625037Phase 1Active Not Recruiting
First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma
NCT07259070Phase 1Not Yet Recruiting
Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma
NCT06474481Phase 2Not Yet RecruitingPrimary
Zanubrutinib and G-CHOP in Untreated Intermediate-high Risk Follicular Lymphoma
Showing all 3 trials